Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
CA 2344107 A1 · Owner: Bayer Aktiengesellschaft · Inventors: Schmitz, Gerd; Klucken, Jochen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Modulation of the activity of transmembrane proteins belonging to the ATP binding cassette (ABC) transporter protein family which are etiologically involved in cholesterol driven atherogenic processes and inflammatory diseases like psoriasis, lupus erythematodes and others provides therapeutic means to treat such diseases. Furthermore, detection of herein identified ABC transporter proteins of their respective biochemical activities involved in such atherogenic and inflammatory processes provides diagnostic means for clinical application of diagnosis and monitoring of dyslipidemias atherosclerosis or inflammatory diseases like psoriasis and lupus erythematodes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 21, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 21, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 21, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.